Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2008
Date:11/7/2008


- Quarter Highlighted by Submission of NDA for Novel Antidepressant and

Steady Global Growth for Once-Daily Tramadol -

LAVAL, QC, Nov. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its results for the third quarter ended September 30, 2008. All figures are in Canadian dollars unless otherwise stated.

"We are very pleased with the progress of our business," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Concomitant with the steady sales growth for our once-daily tramadol product globally, we have made strong progress in advancing the programs for our follow on products, highlighted by the submission, in the third quarter, of the NDA for DDS-04A, our novel SARI(1) antidepressant. Our significant efforts to date this year have positioned us to realize a number of value-driving milestones in 2009, including the potential approval of our once-daily tramadol formulation in the U.S., the potential approval and launch of DDS-04A in the U.S., the outcome of the pivotal Phase III study for our twice-daily tramadol-acetaminophen formulation, and the initiation of clinical studies for our first misuse and abuse deterrent combination product."

Financial Summary

Revenue from product sales of Labopharm's once-daily tramadol for the third quarter of fiscal 2008 increased to $3.9 million from $2.8 million for the third quarter of fiscal 2007. In-market sales (i.e. sales by the Company's marketing partners to end users) for once-daily tramadol for Europe(2) experienced strong growth with standard unit sales for the first eight months of 2008 growing by 97% compared to the same period of the previous year. Adjusted gross margin for the third quarter of fiscal 2008 increased to 60% from 56% for the third quarter of fiscal 2007. Research and development and selling, general and administrative expenses for the third quarter of fiscal 2008 were $11.2 million
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
2. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
3. Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
4. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
5. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
6. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
7. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
8. Labopharm Reports Results for First Quarter Fiscal 2008
9. Labopharm announces details for first quarter results conference call and annual meeting
10. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
11. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... July 12, 2014 With prom shopping ... manufacturer and retailer, is ready to showcase its new ... new collection of evening dresses in its online shop. ... 67% off) for these elegant gowns. According to the ... end on July 26, 2014. , He says, ...
(Date:7/12/2014)... Wright & Schulte LLC has filed a DePuy Pinnacle ... Johnson & Johnson, on behalf of an Ohio man who ... DePuy Pinnacle hip replacement and had to undergo revision surgery ... DePuy hip lawsuit was filed July 7, 2014, in the ... where DePuy Pinnacle Hip lawsuit litigation is underway . ...
(Date:7/12/2014)... July 12, 2014 Doylestown Hospital recently ... variety of men’s health questions. Paddock tackles topics ... men, why women live longer than men, and testosterone ... Health Made Simple featured on Doylestown Hospital’s website, ... hernia at any age. If you notice pain, bulging, ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Utah Valley ... of startups, with awards being bestowed to companies in ... Utah’s outstanding entrepreneur community with recognition for new ideas ... model with incoming revenue. , 25 Under 5 highlights ... state that are under 5 years old. Award recipients ...
(Date:7/12/2014)... article released by Seattle's well known plastic surgeon, Dr. Bryan ... cosmetic surgical procedures in summer months . , As ... enliven the rainy Pacific Northwest, many people are turning their ... out as much during the winter as they had planned. ... eager to look their best for their summer vacations, and ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... and regulatory actions make great strides toward establishing ... to develop and test more medications for pediatric ... by experts from Children,s National Medical Center ... issue of Science Translational Medicine. ...
... to research conducted at the Oregon National Primate Research Center ... that oral contraceptives cause weight gain appears to be false. ... appear in next month,s edition of the journal Human ... reveal that contraceptives and the possibility that they may cause ...
... 20, 2011) Cancer scientists led by Dr. John ... at St Jude Children,s Research Hospital (Memphis) have found ... carry them are organized in a more complex way ... in Nature (DOI:10.1038/nature09733), challenge the conventional scientific ...
... N.Y. (January 19, 2011) Autism Speaks, North America,s ... announce the expansion of its Autism Treatment Network to ... in the U.S. and Canada. The Autism Speaks Autism ... and healthcare for children and adolescents with autism spectrum ...
... -- Parents may have good reason to be concerned ... playing their new video games since the holidays. A ... an Iowa State University psychologist -- found further evidence ... amounts of gaming, lower social competence and greater impulsivity ...
... is available in German . Malignant ... depending on disease stage. Experts hope that the examination of ... helpful in the choice of the right treatment than other ... and Efficiency in Health Care (IQWiG) has now investigated the ...
Cached Medicine News:Health News:Science Translational Medicine: 'Creating Hope Act' incentivizes pediatric drug R&D 2Health News:Do birth control pills cause weight gain? New research says no 2Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 2Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 3Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 2Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 3Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 4Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 5Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 6Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 7Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 8Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 9Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 10Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 11Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 12Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 13Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 14Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 15Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 16Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 17Health News:Autism Speaks Autism Treatment Network expands to 17 sites in North America 18Health News:New Pediatrics study identifies the risks, consequences of video game addiction 2Health News:New Pediatrics study identifies the risks, consequences of video game addiction 3Health News:Malignant brain tumors: Benefit of PET and PET/CT in the detection of recurrences is not assessable 2
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
(Date:7/10/2014)...  Decision Resources Group finds that while more ... are willing to prescribe Durata,s Dalvance (dalbavancin) and ... OPAT, approximately two-thirds of the respondents reported a ... inpatients. However, our findings indicate that nearly two-thirds ... OPAT following hospital discharge, and most are discharged ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Resveratrol, Sirtuin1 gene Target Discredited; Lower Dose, Array ... Small Molecules (Longevinex(R)) Exert Greater Effect, SAN ... wine molecule,resveratrol (rez-vair-ah-trawl) has recently attracted scientific and,public ... the effects,of a calorie-restricted diet, the science surrounding ...
... Alpharma Inc.,(NYSE: ALO ), a global ... Phase III pivotal efficacy trial that showed ... capsules provided significant pain relief in patients ... of the hip or knee compared,to placebo. ...
Cached Medicine Technology:Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged 2Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged 3Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 2Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 5
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists....
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
Electric high speed system....
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm....
Medicine Products: